Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN

Background:<br/> Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort.<...

Full description

Bibliographic Details
Main Authors:	Ledder, O, Assa, A, Levine, A, Escher, J, de Ridder, L, Ruemmele, F, Shah, N, Shaoul, R, Wolters, V, Rodrigues, A, Uhlig, H, Posovsky, C, Kolho, K, Jakobsen, C, Cohen, S, Shouval, D, de Meij, T, Martin-de-Carpi, J, Richmond, L, Bronsky, J, Friedman, M, Turner, D
Format:	Journal article
Language:	English
Published:	Oxford University Press 2017

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN

Similar Items